Research Area: Neurological Disease Biological Activity: Benserazide is a peripherally-acting aromatic L-amino acid decarboxylase (AAAD) or DOPA decarboxylase inhibitor. It inhibits this decarboxylation, and since it itself cannot cross the blood-brain barrier, this allows dopamine to build up solely in the brain instead. Adverse effects caused by peripheral dopamine, such as nausea and arrhythmia, are minimized. However, benserazide cannot reduce the centrally-mediated side effects of levodopa, particularly dyskinesia. [1][2]
A hydrochloride that is the monohydrochloride salt of benserazide. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide hydrochloride has no antiparkinson actions when given alone.
参考文献
PubChem文献
数据源提供
• http://en.wikipedia.org/wiki/Benserazide
• Burkard, W.P., et al.: Experientia, 18, 411 (1962)
• Marion, M.-H., et al.: Adv. Neurol., 45, 493 (1962)